Table 3.
Mutations in CHD components reported in TCGA publications.
| Gene | Cancer type | Data source | No. of mutations | No. of total | % of mutations |
|---|---|---|---|---|---|
| CHD1 | Bladder | Bladder Urothelial Carcinoma (TCGA, Nature 2014) | 7 | 130 | 5.4% |
| Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 7 | 72 | 9.7% | |
| Colorectal Adenocarcinoma (TCGA, Nature 2012) | 9 | 225 | 4.0% | ||
| Stomach | Stomach Adenocarcinoma (UHK, Nature Genetics 2011) | 2 | 22 | 9.1% | |
| CDH2 | Bladder | Bladder Urothelial Carcinoma (BGI, Nature Genetics 2013) | 4 | 100 | 4.0% |
| Bladder Urothelial Carcinoma (TCGA, Nature 2014) | 12 | 130 | 9.2% | ||
| Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 3 | 71 | 4.2% | |
| Colorectal Adenocarcinoma (TCGA, Nature 2012) | 10 | 222 | 4.5% | ||
| Colorectal Adenocarcinoma (TCGA, Provisional) | 10 | 222 | 4.5% | ||
| Stomach | Stomach Adenocarcinoma (Pfizer and UHK, Nature Genetics 2014) | 7 | 100 | 7.0% | |
| Stomach Adenocarcinoma (TCGA, Nature 2014) | 12 | 286 | 4.2% | ||
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 16 | 246 | 6.5% | |
| CHD3 | Bladder | Bladder Urothelial Carcinoma (TCGA, Nature 2014) | 6 | 130 | 4.6% |
| Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 7 | 72 | 9.7% | |
| Colorectal Adenocarcinoma (TCGA, Nature 2012) | 10 | 222 | 4.5% | ||
| Stomach | Stomach Adenocarcinoma (Pfizer and UHK, Nature Genetics 2014) | 4 | 100 | 4.0% | |
| Stomach Adenocarcinoma (TCGA, Nature 2014) | 19 | 288 | 6.6% | ||
| Stomach Adenocarcinoma (TCGA, Provisional) | 14 | 222 | 6.3% | ||
| Stomach Adenocarcinoma (UHK, Nature Genetics 2011) | 2 | 22 | 9.1% | ||
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 26 | 248 | 10.5% | |
| CHD4 | Bladder | Bladder Urothelial Carcinoma (TCGA, Nature 2014) | 9 | 130 | 6.9% |
| Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 4 | 71 | 5.6% | |
| Colorectal Adenocarcinoma (TCGA, Nature 2012) | 17 | 224 | 7.6% | ||
| Lung | Lung Adenocarcinoma (Broad, Cell 2012) | 4 | 182 | 2.2% | |
| Lung Adenocarcinoma (TCGA, Nature 2014) | 6 | 231 | 2.6% | ||
| Lung Squamous Cell Carcinoma (TCGA, Nature 2012) | 11 | 177 | 6.2% | ||
| Melanoma | Melanoma (Broad/Dana Farber, Nature 2012) | 2 | 25 | 8.0% | |
| Cutaneous Melanoma (Broad, Cell 2012) | 11 | 121 | 9.1% | ||
| Cutaneous Melanoma (Yale, Nature Genetics 2012) | 6 | 91 | 6.6% | ||
| Stomach | Stomach Adenocarcinoma (TCGA, Nature 2014) | 26 | 289 | 9.0% | |
| Stomach Adenocarcinoma (UHK, Nature Genetics 2011) | 1 | 22 | 4.5% | ||
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 35 | 248 | 14.1% | |
| CDH5 | Head & neck | Head and Neck Squamous Cell Carcinoma (Broad, Science 2011) | 3 | 73 | 4.1% |
| Melanoma | Melanoma (Broad/Dana Farber, Nature 2012) | 1 | 25 | 4.0% | |
| Cutaneous Melanoma (Broad, Cell 2012) | 9 | 122 | 7.4% | ||
| CDH6 | Bladder | Bladder Urothelial Carcinoma (BGI, Nature Genetics 2013) | 5 | 98 | 5.1% |
| Bladder Urothelial Carcinoma (TCGA, Nature 2014) | 10 | 130 | 7.7% | ||
| Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 9 | 72 | 12.5% | |
| Colorectal Adenocarcinoma (TCGA, Nature 2012) | 16 | 225 | 7.1% | ||
| Lung | Lung Adenocarcinoma (Broad, Cell 2012) | 9 | 184 | 4.9% | |
| Lung Adenocarcinoma (TCGA, Nature 2014) | 13 | 228 | 5.7% | ||
| Small Cell Lung Cancer (CLCGP, Nature Genetics 2012) | 2 | 29 | 6.9% | ||
| Small Cell Lung Cancer (Johns Hopkins, Nature Genetics 2012) | 2 | 42 | 4.8% | ||
| Melanoma | Cutaneous Melanoma (Broad, Cell 2012) | 11 | 121 | 9.1% | |
| Cutaneous Melanoma (Yale, Nature Genetics 2012) | 6 | 91 | 6.6% | ||
| Melanoma | Melanoma (Broad/Dana Farber, Nature 2012) | 2 | 25 | 8.0% | |
| Prostate | Prostate Adenocarcinoma, Metastatic (Michigan, Nature 2012) | 3 | 61 | 4.9% | |
| Metastatic Prostate Cancer, SU2C/PCF Dream Team (Robinson et al., Cell 2015) | 6 | 150 | 4.0% | ||
| Stomach | Stomach Adenocarcinoma (TCGA, Nature 2014) | 29 | 290 | 10.0% | |
| Stomach Adenocarcinoma (UHK, Nature Genetics 2011) | 1 | 22 | 4.5% | ||
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 20 | 247 | 8.1% | |
| CDH7 | Bladder | Bladder Urothelial Carcinoma (TCGA, Nature 2014) | 13 | 130 | 10.0% |
| Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 7 | 72 | 9.7% | |
| Colorectal Adenocarcinoma (TCGA, Nature 2012) | 9 | 225 | 4.0% | ||
| Lung | Lung Adenocarcinoma (Broad, Cell 2012) | 11 | 183 | 6.0% | |
| Lung Adenocarcinoma (TCGA, Nature 2014) | 12 | 231 | 5.2% | ||
| Lung Squamous Cell Carcinoma (TCGA, Nature 2012) | 13 | 178 | 7.3% | ||
| Medulloblastoma | Medulloblastoma (PCGP, Nature 2012) | 3 | 37 | 8.1% | |
| Melanoma | Cutaneous Melanoma (Broad, Cell 2012) | 6 | 120 | 5.0% | |
| Melanoma (Broad/Dana Farber, Nature 2012) | 3 | 25 | 12.0% | ||
| Stomach | Stomach Adenocarcinoma (Pfizer and UHK, Nature Genetics 2014) | 5 | 100 | 5.0% | |
| Stomach Adenocarcinoma (TCGA, Nature 2014) | 27 | 290 | 9.3% | ||
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 20 | 247 | 8.1% | |
| CDH8 | Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 7 | 72 | 9.7% |
| Esophagus | Esophageal Adenocarcinoma (Broad, Nature Genetics 2013) | 6 | 146 | 4.1% | |
| Head & neck | Head and Neck Squamous Cell Carcinoma (Broad, Science 2011) | 3 | 73 | 4.1% | |
| Lung | Lung Adenocarcinoma (TCGA, Nature 2014) | 12 | 231 | 5.2% | |
| Small Cell Lung Cancer (Johns Hopkins, Nature Genetics 2012) | 3 | 42 | 7.1% | ||
| Lung Squamous Cell Carcinoma (TCGA, Nature 2012) | 10 | 179 | 5.6% | ||
| Melanoma | Cutaneous Melanoma (Broad, Cell 2012) | 8 | 121 | 6.6% | |
| Melanoma (Broad/Dana Farber, Nature 2012) | 2 | 25 | 8.0% | ||
| Prostate | Prostate Adenocarcinoma, Metastatic (Michigan, Nature 2012) | 3 | 61 | 4.9% | |
| Stomach | Stomach Adenocarcinoma (TCGA, Nature 2014) | 17 | 288 | 5.9% | |
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 19 | 247 | 7.7% | |
| CDH9 | Bladder | Bladder Urothelial Carcinoma (TCGA, Nature 2014) | 8 | 129 | 6.2% |
| Colorectal | Colorectal Adenocarcinoma (Genentech, Nature 2012) | 6 | 72 | 8.3% | |
| Colorectal Adenocarcinoma (TCGA, Nature 2012) | 11 | 224 | 4.9% | ||
| Lung | Lung Adenocarcinoma (Broad, Cell 2012) | 13 | 183 | 7.1% | |
| Lung Adenocarcinoma (TCGA, Nature 2014) | 10 | 233 | 4.3% | ||
| Melanoma | Cutaneous Melanoma (Broad, Cell 2012) | 7 | 121 | 5.8% | |
| Melanoma (Broad/Dana Farber, Nature 2012) | 2 | 25 | 8.0% | ||
| Stomach | Stomach Adenocarcinoma (TCGA, Nature 2014) | 16 | 291 | 5.5% | |
| Uterine | Uterine Corpus Endometrioid Carcinoma (TCGA, Nature 2013) | 17 | 246 | 6.9% |